Key Points
- EVP Michael Erickson sold 5,371 IDEXX shares on Feb. 17 at an average price of $627.38 for about $3.37 million, reducing his stake by 29.73% to 12,693 shares; the transaction was disclosed in an SEC filing.
- IDEXX beat revenue in the quarter ($1.09B, +14.3% year-over-year) but missed EPS by $0.01 ($2.92), set FY2026 EPS guidance of $14.29–14.80, and carries an average analyst price target of $783.33 with a consensus rating of “Moderate Buy.”
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) Director Sophie Vandebroek sold 1,464 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director owned 648 shares of the company's stock, valued at approximately $407,345.76. This represents a 69.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
IDEXX Laboratories Stock Up 0.6%
IDXX stock traded up $3.69 during mid-day trading on Friday, hitting $634.42. The stock had a trading volume of 73,037 shares, compared to its average volume of 493,658. The stock has a market capitalization of $50.66 billion, a price-to-earnings ratio of 48.62, a PEG ratio of 3.86 and a beta of 1.67. The company has a fifty day moving average of $679.11 and a 200 day moving average of $669.15. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the firm earned $2.53 earnings per share. IDEXX Laboratories's revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have commented on IDXX. Jefferies Financial Group reaffirmed a "buy" rating and issued a $830.00 price target on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Piper Sandler lowered their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research note on Monday, February 9th. Wall Street Zen raised IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a report on Saturday, February 7th. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, Barclays dropped their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $783.33.
Get Our Latest Analysis on IDXX
Institutional Investors Weigh In On IDEXX Laboratories
Institutional investors have recently made changes to their positions in the stock. Blalock Williams LLC purchased a new stake in IDEXX Laboratories during the third quarter worth about $590,000. New York State Common Retirement Fund lifted its stake in IDEXX Laboratories by 6.8% in the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company's stock valued at $38,477,000 after purchasing an additional 3,820 shares during the last quarter. Arkadios Wealth Advisors purchased a new stake in IDEXX Laboratories in the second quarter worth $405,000. Mediolanum International Funds Ltd grew its stake in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company's stock worth $24,441,000 after acquiring an additional 4,909 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company's stock worth $840,638,000 after acquiring an additional 187,967 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.
About IDEXX Laboratories
(
Get Free Report)
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
